Two proteomics studies reported actionable molecular signatures: one used quantitative proteomics to characterize Mucin‑16 alterations in low‑grade serous ovarian cancer (Clinical Proteomics), and another profiled plasma exosome proteomes in metastatic colorectal cancer. Both efforts aimed to refine biomarker panels for diagnosis and therapeutic stratification. The ovarian cancer work identifies MUC‑16 post‑translational changes that may inform targeted approaches and patient selection. The metastatic colorectal cancer study maps exosome cargo correlating with disease state and treatment response, proposing noninvasive monitoring candidates. Translational groups and diagnostic developers will assess assay robustness, cohort validation, and regulatory routes for companion diagnostics or liquid‑biopsy products based on these findings.